Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20819384 | 1.00 | HIF1A (0.55) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL31291101 | 1.00 | HIF1A (0.55) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL22481252 | 0.84 | HIF1A (0.51) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL22481311 | 0.84 | HIF1A (0.51) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL20819349 | 0.83 | HIF1A (0.50) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL10361058 | 0.83 | LMNA (0.50) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL20819364 | 0.83 | ADRB2 (0.52) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL17273622 | 0.83 | HIF1A (0.50) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL20819365 | 0.83 | ADRB2 (0.52) | HIF1ALMNAADRB2CASP7KMT2A | |
| SCHEMBL20819357 | 0.83 | HIF1A (0.50) | HIF1ALMNAADRB2CASP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3952101-A | BETA ADRENERGIC STIMULANT | SMITHKLINE CORPORATION (US) | 1976-04-20 | — | — | US | claimed |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-12-05 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-11357757-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2022-06-14 | — | — | US | disclosed |
| US-20220133703-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-05-05 | — | — | US | disclosed |
| EP-3971168-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2022-03-23 | — | — | EP | disclosed |
| EP-3681872-B1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-11-17 | — | — | EP | disclosed |
| EP-3681872-B1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-11-17 | — | — | EP | disclosed |
| US-20210030731-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2021-02-04 | — | — | US | disclosed |
| EP-3681872-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019053427-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053427-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| US-4632992-A | Intermediates for preparing pirbuterol and analogs | PFIZER INC. (US) | 1986-12-30 | — | — | US | disclosed |
| EP-0058069-B1 | PROCESS AND INTERMEDIATES FOR PREPARING PIRBUTEROL AND ANALOGS | PFIZER INC. (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4477671-A | 3-Acetoxy or benzyloxy-2-acetoxymethyl-6-[1-acetoxy-2-(N-tert-butylacetamido)ethyl]pyridine intermediates | PFIZER INC. (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0058070-A3 | PROCESS FOR PREPARING PIRBUTEROL | PFIZER INC. (US) | 1982-08-25 | — | — | EP | disclosed |
| EP-0058070-A2 | Process for preparing pirbuterol | PFIZER INC. (US) | 1982-08-18 | — | — | EP | disclosed |
| EP-0058070-A2 | Process for preparing pirbuterol | PFIZER INC. (US) | 1982-08-18 | — | — | EP | disclosed |
| EP-0058069-A2 | Process and intermediates for preparing pirbuterol and analogs | PFIZER INC. (US) | 1982-08-18 | — | — | EP | disclosed |
| US-3952101-A | BETA ADRENERGIC STIMULANT | SMITHKLINE CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133703-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885 |
| US-11357757-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885 |
| US-20240398770-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | HIF1A 688/4885LMNA 2140/4885ADRB2 92/4885 |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885 |
| US-20210030731-A1 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA | SLC5A2, SLC5A1, GPR119 | HIF1A 707/4885LMNA 2131/4885ADRB2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.